Moving Developmental Toxicology Toward Mechanism-Based Testing

Moving Developmental Toxicology Toward Mechanism-Based Testing

1. The Traditional Model: Effective but Limited

Developmental toxicity testing has long relied on traditional testing methods, largely based on standardized animal studies. Commonly, pregnant rats or rabbits are exposed to a substance, and outcomes such as fetal malformations, growth retardation, embryo-fetal death, or functional deficits are evaluated. This testing paradigm emerged after the thalidomide tragedy (1957–1961) and has remained largely unchanged for decades.

While these studies capture outcomes that are relevant to human health, they also come with limitations. Differences in metabolism and pharmacodynamics between species can sometimes lead to inaccurate conclusions about human developmental toxicity. At the same time, these studies are resource-intensive and rely heavily on animal models.

Most importantly, this traditional developmental toxicity testing approach is mainly observational and protocol-driven, focusing on detecting adverse outcomes rather than understanding the biological mechanisms underlying them.

2. A Shift Toward Hypothesis-Driven Developmental Toxicology

Recent advances in molecular biology now allow a more hypothesis-driven approach to developmental toxicity assessment. Instead of relying solely on traditional developmental toxicity testing, researchers can investigate the mode of action (MoA) of chemicals and identify the molecular and cellular events that lead to adverse developmental outcomes.

This approach shifts the focus from simply observing effects in whole animals to testing specific biological hypotheses about how chemicals disrupt developmental processes.

Tools such as transcriptomics, high-throughput screening batteries, and computational methods can help identify biological pathways affected by chemicals and generate hypotheses about their potential toxicity.

For example, large datasets of gene expression profiles can reveal patterns associated with specific mechanisms of toxicity, while high-throughput screening platforms allow researchers to test chemical interactions with biological targets across many pathways simultaneously.

Two Paradigms in Developmental Toxicology

3. Human-Relevant Models Are Already Available

Advances in stem-cell biology have further expanded the toolbox for developmental toxicology. Human pluripotent stem cell models can replicate aspects of early development and provide mechanistically relevant systems for toxicity screening.

One example is ReproTracker, a human-induced pluripotent stem cell-based biomarker assay that has demonstrated high accuracy, sensitivity, and specificity in identifying developmental toxicants when compared with traditional in vivo classifications.

These models provide an opportunity to study toxicity in systems that are closer to human biology while reducing reliance on animal testing.

4. The Remaining Challenge: Adoption

Despite the growing availability of mechanistic data and alternative testing tools, their integration into regulatory developmental toxicity assessment remains limited. In practice, alternative approaches are still applied mostly on a case-by-case basis and rarely replace traditional developmental toxicity testing.

The article argues that a hypothesis-driven testing strategy, grounded in mechanistic understanding and supported by new approach methodologies, could make developmental toxicity assessment more efficient and human-relevant and less dependent on animal studies.

The science enabling this transition already exists. The next step is for toxicologists to actively integrate these approaches into routine developmental toxicity assessment.

Learn more on this topic by reading the full article, visiting ReproTracker assay page, or by contacting us.